Aruvant Announces the European Medicines Agency (EMA) Granted Priority Medicines (PRIME) Designation to ARU-1801 for the Treatment of Sickle Cell Disease
New York, NY, Feb. 3, 2021 –Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, today announced that the European Medicines Agency (EMA) granted Priority Medicines (PRIME) designation to ARU-1801, a one-time investigational gene...
Aruvant Chooses Lonza to Manufacture ARU-1801, a Potentially Curative Treatment for Sickle Cell Disease, for Pivotal Trial
New York, NY, Jan. 18, 2021 –Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Lonza announced today their agreement in support of ARU-1801, Aruvant’s one-time investigational gene therapy for sickle cell disease (SCD)....
Aruvant’s Data Presented in Oral Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting Demonstrates Promise of ARU-1801 as a Potentially Curative Treatment for Sickle Cell Disease
–Data from improved manufacturing process resulted in significantly improved ARU-1801 product profile– New York, NY, Dec. 7, 2020 – Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, announced new data demonstrating the...
Aruvant to Participate in SVB Leerink’s Biopharma Private Company Connect December 15 to 17
NEW YORK and BASEL, Switzerland, Dec. 1, 2020 — Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies for the treatment of rare diseases, today announced Will Chou, M.D., Aruvant chief executive...
Aruvant Receives Orphan Designation from European Medicines Agency for Gene Therapy ARU-1801 for Sickle Cell Disease
NEW YORK and BASEL, Switzerland, Nov. 16, 2020 — Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies for the treatment of rare diseases, today announced that the European Medicines Agency (EMA)...
Aruvant Announces Updated Data to be Presented in Oral Presentation of ARU-1801 Data at the 62nd American Society of Hematology (ASH) Annual Meeting
–Ongoing manufacturing improvements shows enhanced efficacy of ARU-1801 for the treatment of sickle cell disease– New York, NY, Nov. 4, 2020 –Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, announced that an abstract...
Sickle Cell Disease Association of America and Aruvant Sciences Forge New Partnership to Educate Around Gene Therapy
Hanover, MD, and New York, NY, October 12, 2020 – The Sickle Cell Disease Association of America (SCDAA) and Aruvant Sciences are proud to announce a new partnership to create educational programs to increase awareness of gene therapy as a potential curative treatment...
Aruvant to Present at Investor and Scientific Conferences in October
NEW YORK and BASEL, Switzerland, Sept. 29, 2020 — Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies for the treatment of rare diseases, today announced it will present at multiple conferences in...